Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

If You Liked Part D, You'll Love Universal Coverage

This article was originally published in RPM Report

Executive Summary

It’s hard to say for sure how big a boost universal coverage would give to pharmaceutical companies’ bottom lines. But the industry’s most recent experience with expanded coverage in the key Medicare market offers some encouraging benchmarks for what to expect.

You may also be interested in...



The Part D Peak: Big Pharma's Blowout Quarter

While many people were watching the Senate grapple with drug price negotiation authority for CMS, Big Pharma blew past Wall Street's expectations with big first quarter gains. One year into the program, Medicare is definitely paying off. But will the party last?

US FDA Credibility: Surprisingly Strong, Despite Everything

A Senate Health Committee update hearing on the COVID-19 federal response was noteworthy primarily for demonstrating that FDA Commissioner Stephen Hahn appears to have salvaged the agency’s position as a voice of credibility with a key political constituency – at least for now.

US FDA’s First Amendment Defense

Before taking over the US health department, Alex Azar helped bring landmark litigation challenging the scope of FDA’s regulatory authority under the First Amendment. Now his tenure is ending with a First Amendment defense of the agency.

Topics

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel